MX363658B - N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos. - Google Patents

N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos.

Info

Publication number
MX363658B
MX363658B MX2015011353A MX2015011353A MX363658B MX 363658 B MX363658 B MX 363658B MX 2015011353 A MX2015011353 A MX 2015011353A MX 2015011353 A MX2015011353 A MX 2015011353A MX 363658 B MX363658 B MX 363658B
Authority
MX
Mexico
Prior art keywords
azaindazol
sulfonamides
pharmaceuticals
phenyl
sgk
Prior art date
Application number
MX2015011353A
Other languages
English (en)
Other versions
MX2015011353A (es
Inventor
Halland Nis
Schmidt Friedemann
Weiss Tilo
Nazaré Marc
Kleemann Heinz-Werner
Saas Joachim
Struebing Carsten
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2015011353A publication Critical patent/MX2015011353A/es
Publication of MX363658B publication Critical patent/MX363658B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a N-(4-(azaindazol-6-il)-fenil)-s ulfonamidas de fórmula I, (ver Fórmula) en la que Ar, n, X, Z, R1, R2 y R3 tienen los significados indicados en las reivindicaciones. Los compuestos de fórmula I son valiosos compuestos farmacológicamente activos que modulan la actividad de proteína quinasa, específicamente la actividad de quinasa regulada por suero y glucocorticoides (SGK), en particular de la isoforma 1 de la quinasa regulada por suero y glucocorticoides (SGK-1, SGK1), y son adecuados para el tratamiento de enfermedades en las que la actividad de SGK es inapropiada, por ejemplo trastornos degenerativos de las articulaciones o procesos inflamatorios tales como osteoartritis o reumatismo. La invención se refiere además a procesos para la preparación de los compuestos de fórmula I, a su uso como productos farmacéuticos, y a composiciones farmacéuticas que comprenden los mismos.
MX2015011353A 2013-03-13 2014-03-12 N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos. MX363658B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305283 2013-03-13
PCT/EP2014/054770 WO2014140065A1 (en) 2013-03-13 2014-03-12 N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals

Publications (2)

Publication Number Publication Date
MX2015011353A MX2015011353A (es) 2015-12-16
MX363658B true MX363658B (es) 2019-03-28

Family

ID=48040124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011353A MX363658B (es) 2013-03-13 2014-03-12 N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos.

Country Status (24)

Country Link
US (1) US9718825B2 (es)
EP (1) EP2970259B1 (es)
JP (1) JP6404241B2 (es)
KR (2) KR102219160B1 (es)
CN (1) CN105189502B (es)
AR (1) AR095279A1 (es)
AU (1) AU2014230805B2 (es)
BR (1) BR112015020287B1 (es)
CA (2) CA3111517A1 (es)
CY (1) CY1119151T1 (es)
DK (1) DK2970259T3 (es)
ES (1) ES2618213T3 (es)
HR (1) HRP20170337T1 (es)
HU (1) HUE031540T2 (es)
IL (1) IL240178A (es)
LT (1) LT2970259T (es)
MX (1) MX363658B (es)
PL (1) PL2970259T3 (es)
PT (1) PT2970259T (es)
RU (1) RU2671864C2 (es)
SG (1) SG11201506093SA (es)
SI (1) SI2970259T1 (es)
TW (1) TWI629275B (es)
WO (1) WO2014140065A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINED THERAPY USING PDK1 AND PI3K INHIBITORS
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
TWI651308B (zh) * 2016-09-23 2019-02-21 瑞士商諾華公司 用於肌腱及／或韌帶傷害之吲唑化合物
US11236083B2 (en) 2016-12-07 2022-02-01 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
KR20200036004A (ko) * 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
WO2020060268A1 (ko) 2018-09-20 2020-03-26 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
US20220388964A1 (en) * 2019-04-12 2022-12-08 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
CN110379468B (zh) * 2019-07-17 2022-08-23 成都火石创造科技有限公司 一种改进的化学分子式切分方法
JP2024502178A (ja) * 2021-01-13 2024-01-17 スリブ セラピューティクス インコーポレイテッド Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体
EP4147700A1 (en) 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
WO2024011316A1 (en) * 2022-07-12 2024-01-18 Thryv Therapeutics Inc. Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-fluorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824121A (en) 1954-11-04 1958-02-18 Kay Fries Chemicals Inc Process for preparation of oxy alkylidene compounds
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ES2309206T3 (es) * 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
DE102004059781A1 (de) 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
CA2664375A1 (en) * 2006-09-28 2008-04-03 Novartis Ag Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use
DE102007002717A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
EP2789615B1 (en) * 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
AU2011377409B2 (en) * 2011-09-19 2017-05-25 Sanofi N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
JP5827849B2 (ja) * 2011-09-20 2015-12-02 サノフイ Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用

Also Published As

Publication number Publication date
BR112015020287A2 (pt) 2017-07-18
US20160024097A1 (en) 2016-01-28
CA2901534C (en) 2021-04-27
CA2901534A1 (en) 2014-09-18
IL240178A (en) 2016-08-31
AR095279A1 (es) 2015-09-30
CN105189502A (zh) 2015-12-23
CA3111517A1 (en) 2014-09-18
BR112015020287B1 (pt) 2022-12-13
TW201512194A (zh) 2015-04-01
MX2015011353A (es) 2015-12-16
US9718825B2 (en) 2017-08-01
TWI629275B (zh) 2018-07-11
RU2671864C2 (ru) 2018-11-07
JP6404241B2 (ja) 2018-10-10
AU2014230805B2 (en) 2018-02-15
KR20210021127A (ko) 2021-02-24
EP2970259A1 (en) 2016-01-20
RU2015143000A (ru) 2017-04-20
HRP20170337T1 (hr) 2017-04-21
WO2014140065A1 (en) 2014-09-18
JP2016514116A (ja) 2016-05-19
SI2970259T1 (sl) 2017-05-31
SG11201506093SA (en) 2015-09-29
CY1119151T1 (el) 2018-02-14
LT2970259T (lt) 2017-03-27
EP2970259B1 (en) 2016-12-21
PT2970259T (pt) 2017-03-10
KR20150130443A (ko) 2015-11-23
HUE031540T2 (en) 2017-07-28
KR102219160B1 (ko) 2021-02-23
AU2014230805A1 (en) 2015-09-24
IL240178A0 (en) 2015-09-24
ES2618213T3 (es) 2017-06-21
PL2970259T3 (pl) 2017-06-30
DK2970259T3 (en) 2017-03-20
CN105189502B (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
MX363658B (es) N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos.
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MX342869B (es) N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos.
MX2021013941A (es) Inhibidores del inflamasoma nlrp3.
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
NZ708593A (en) Novel pyrazole derivative
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
BR112014009102A2 (pt) compostos químicos
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
CR20210101A (es) Compuestos heteroaromáticos como inhibidores de vanina
PH12015500795A1 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
WO2017168454A3 (en) Novel compounds as btk inhibitors
EA202190452A1 (ru) Ингибиторы cdk8/19
EA202190329A1 (ru) Ингибиторы инфламмасомы nlrp3